Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage surgery plus camrelizumab and nimotuzumab for locally recurrent nasopharyngeal carcinoma after re-irradiation
ChiCTR2100053094Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: 2-year survival rate. Started Nov 2021; status: recruiting.
02
Drugs
camrelizumabnimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100053094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053094.